Search PubMed⌕ Search

Biomedical subjects

J F Larsen

Publications and source records attributed to J F Larsen.

At least 91 records · Page 5Linked to original sources
PubMed1980

Ritodrine in the treatment of preterm labour. A clinical trial to compare a standard treatment with three regimens involving the use of ritodrine.

In a randomized trial, three alternative schemes of treatment of preterm labour with ritodrine (long infusion, short infusion, and intramuscular injection) were compared with standard treatment by bed rest and sedatives. None of the ritodrine treatments were found to be better in postponing delivery than the standard treatment. However, the Bishop scores of the patients in the standard treatment group tended to be lower than of the patients treated with ritodrine. Moreover, all cases of congenital malformation and polyhydramnios occurred in the patients treated with ritodrine. The incidence of respiratory insufficiency was significantly higher in infants of mothers treated with ritodrine. The mean birth weight was highest in the standard treatment group.

Adult↗
PubMed1980

Progesterone and human chorionic gonadotrophin in serum and pregnandiol in urine in threatened abortion.

Progesterone and human chorionic gonadotrophin (HCG) in serum and pregnandiol in urine were measured in 64 patients admitted to hospital because of threatened abortion. Blood samples were taken and urine specimens collected at regular intervals during admission and after discharge during the rest of the pregnancy. A reference range was worked out for each hormone based on the hormone values obtained from the pregnancies proceeding to term. The predictive significance of values within and below the reference range was determined, for the initial sample and for serial samples. An association between hormone levels and outcome of pregnancy was observed but it is concluded that both single and serial determinations of progesterone and pregnandiol and serial determinations of HCG are unsatisfactory for the evaluation of threatened abortion. However, an initial progesterones value below the reference range and HCG values below 10,000 mIU/ml between the 8th and 15th week of pregnancy was in every case always followed by spontaneous abortion. A hormonal test of fetoplacental origin is recommended for monitoring threatened abortion.

Abortion, Threatened↗
PubMed1979

Estradiol, estriol and human placental lactogen in serum in threatened abortion.

In 64 pregnant women admitted to hospital because of threatened abortion the prognostic value of estradiol-17-beta, estriol and human placental lactogen (HPL) in serum was examined. The hormones were determined by radioimmunoassay. Blood samples were taken at regular intervals during admission to hospital and subsequently until delivery. For each hormone a reference range was based on the hormone values obtained from the pregnancies that continued to viability. The study shows that the three hormones examined gave a good indication of the prognosis in threatened abortion, both separately and in combination. The best predictive values were achieved with estradiol and HPL after serial samples. Of these two hormones estradiol is to be preferred because of its fetoplacental origin.

Abortion, Threatened↗
PubMed1979

Treatment of hyperprolactinemic luteal insufficiency with bromocriptine.

Twelve patients with infertility and insufficent luteal function were studied during a control cycle, and during a cycle when 2.5 mg of bromocriptine was given twice daily. Serum levels of prolactin, progesterone, estradiol-17-beta, FSH and LH were determined during both cycles. Endometrial biopsies were taken from most patients during the late luteal phase. Two patients had persistent hyperprolactinemia, approximately 35-45 ng/ml, and both had repeated insufficient luteal function, which completely reverted to normal during treatment. Five of the 10 normoprolactinemic patients achieved a normal luteal function during bromocriptine therapy. No pregnancies were achieved during the study but one patient later conceived during bromocriptine therapy.

Adult↗
PubMed1978

Correlations between prolactin and progesterone, oestradiol-17-beta and oestriol during early human pregnancy.

The correlations between serum prolactin and progesterone, oestradiol-17-beta and oestriol were determined in 125 pregnant females between the sixth and fourteenth week of pregnancy. No significant correlations were found between prolactin and progesterone. Correlations between prolactin and oestradiol-17-beta and oestriol were mostly positive, but only significant during the twelfth week of pregnancy.

Estradiol↗
PubMed1978

Intrauterine injection of vitamin K before the delivery during anticoagulant therapy of the mother.

The coagulation factors PP% (Factors II+IV), factor IX and factor X were determined in infants born by mothers receiving anticoagulants. The factors were very low when the mothers did not receive vitamin K before the delivery. No significant improvement in the factors was observed after an intravenous or intraamniotic injection of vitamin K two to four days before the delivery. Vitamin K was injected intramuscularly into four foetuses in utero using an ultrasonic multitransducer scanner. Three of these infants had normal coagulation factors at birth. In the fourth case the factor X was normal and factor IX was significantly better than in the infants of the other groups. The injection had no harmful effects to the infants.

Adult↗
PubMed1977

Effect of bromocriptine on the premenstrual syndrome. A double-blind clinical trial.

Twenty-one patients suffering from the premenstrual syndrome were each studied during three menstrual cycles. After a control cycle, bromocriptine and placebo were given during the luteal phase of the cycle in a random double-blind cross-over manner, each patient serving as her own control. The dosage of bromocriptine was 2-5 mg twice daily. Serum prolactin levels were found to equal during the follicular and luteal phases, except when reduced by bromocriptine. Serum progesterone and oestradiol-17-beta were within normal ranges, and did not change during treatment. Medication considerably improved all the premenstrual symptoms, but mastodynia was the only one where bromocriptine was significantly better than the placebo.

Adolescent↗